Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004552 · ClinicalTrials.gov registry record · Phase 2
Acamprosate Treatment: Mechanisms of Action
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00004552 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 120 participants.
The verdict
NCT00004552, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study will examine whether pretreatment with two doses of acamprosate for seven days prior to abstinence lessens the intensity of acute withdrawal from alcohol compared with a placebo. Subjects will be randomly assigned to receive either one of two doses of acamprosate or placebo for seven days. This will be followed by a four- day inpatient period when withdrawal will be monitored. Additional drinking information will be obtained at a three month followup interview.
Interventions
- DRUG acamprosate (Campral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004552
The ClinicalTrials.gov registry entry for NCT00004552 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which acamprosate (Campral) is the first listed.
NCT00004552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004552 about?
NCT00004552 is a clinical study titled "Acamprosate Treatment: Mechanisms of Action". This study will examine whether pretreatment with two doses of acamprosate for seven days prior to abstinence lessens the intensity of acute withdrawal from alcohol compared with a placebo. Subjects will be randomly assigned to receive either one of two doses of acamprosate or placebo for seven days...
What is the current status of trial NCT00004552?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00004552?
The interventions under investigation include: acamprosate (Campral) (DRUG).
Who is sponsoring clinical trial NCT00004552?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.